⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Earlier Initiation of Ublituximab Treatment Is Associated with Improved Disability Outcomes Among Treatment Naïve Participants in ULTIMATE I and II (P9-6.001)

Derrick Robertson Hans‐Peter Hartung Peiqing Qian Sibyl Wray Lily Lee Koby Mok Christopher Garner Enrique Álvarez

View at Publisher

Ask AI

Bookmark

Share

Abstract

To evaluate disease progression in treatment naïve participants enrolled in ULTIMATE I and II stratified by time since first MS symptom.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Robertson et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677fab https://doi.org/10.1212/wnl.0000000000206441

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Five Years of Ublituximab in Multiple SclerosisHuman Clinical Trial · 2026 · 10 citations
2Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies (P9-6.017)2024
3Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinionreview · 2025 · 3 citations
4Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)Human Clinical Trial · 2026
5Real World Clinical Experience from ENABLE, the First Phase Four Observational Study for Patients With Relapsing Multiple Sclerosis Initiating Ublituximab (P9-19.005)Observational Study · 2026

Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study2025
MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide (P3-6.001)2024
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis Treatment2025
Clinical Reasoning: A 60-Year-Old Woman With Progressive Dysarthric Speech and Gait InstabilityNeurology · 2026
Maternal and Fetal Safety Outcomes of Thrombolytics for Ischemic Stroke in PregnancyNeurology · 2026

More from Neurology

More from Heinrich Heine University Düsseldorf

More from University of South Florida

More from University of Colorado System

More from HOPE Clinic

More from CDG Therapeutics (United States)